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Abstract
Background: The CogState Schizophrenia Battery (CSB), a computerized cognitive battery, covers all the same cognitive
domains as the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus
Cognitive Battery but is briefer to conduct. The aim of the present study was to evaluate the criterion and construct validity
of the Japanese language version of the CSB (CSB-J) in Japanese patients with schizophrenia.
Methodology/Principal Findings: Forty Japanese patients with schizophrenia and 40 Japanese healthy controls with
matching age, gender, and premorbid intelligence quotient were enrolled. The CSB-J and the Brief Assessment of Cognition
in Schizophrenia, Japanese-language version (BACS-J) were performed once. The structure of the CSB-J was also evaluated
by a factor analysis. Similar to the BACS-J, the CSB-J was sensitive to cognitive impairment in Japanese patients with
schizophrenia. Furthermore, there was a significant positive correlation between the CSB-J composite score and the BACS-J
composite score. A factor analysis showed a three-factor model consisting of memory, speed, and social cognition factors.
Conclusions/Significance: This study suggests that the CSB-J is a useful and rapid automatically administered computerized
battery for assessing broad cognitive domains in Japanese patients with schizophrenia.
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Introduction
Cognitiveimpairment,acoresymptomofschizophrenia,ispresent
at illness onset and usually persists even when psychotic symptoms
have been successfully treated [1,2]. Furthermore, cognitive
impairment is highly related to functional outcome in patients with
schizophrenia [3,4]. Therefore, treatment of cognitive impairment is
currently an important focus for psychopharmacology [5–10].
In contrast, the lack of an accepted standard battery for
measuring cognitive impairment in patients with schizophrenia
had been a major obstacle to regulatory approval of cognition-
enhancing treatments. Currently, National Institute of Mental
Health - Measurement and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS) initiative - Consensus
Cognitive Battery (MCCB) is available for the measurement of
cognitive changes in patients with schizophrenia [11,12]. The
MCCB has seven domains of cognitive function, including verbal
learning, speed of processing, attention/vigilance, working mem-
ory, visual learning, reasoning and problem solving, and social
cognition [11]. The MCCB was approved by Food and Drug
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in schizophrenia [13]. However, a Japanese version of the MCCB
is not yet available. In contrast, the Japanese language version of
the Brief Assessment of Cognition in Schizophrenia (BACS)
[14,15] has been used to measure cognitive impairments in
Japanese patients with schizophrenia.
Like the BACS, the CogState Schizophrenia Battery (CSB) has
been developed to provide a briefer standardized assessment of
cognition in schizophrenia. Although the BACS includes only four
of the seven cognitive domains of the MATRICS initiative
[16,17], the CSB includes all the seven cognitive domains [18,19].
Formal validation studies have shown the CSB to have very good
sensitivity to cognitive impairment in patients with chronic
schizophrenia, and require approximately 40 min for administra-
tion [18,19]. There is also a strong correlation between the
composite scores from the CSB and the MCCB measures in
patients with schizophrenia. Furthermore, both composite scores
also correlate strongly with scores on Performance-Based Skills
Assessment [19]. Importantly, because the CSB was developed
specifically for the measurement of cognitive change the
component tasks show minimal practice effects with repeated
assessment, even during very brief re-test intervals [19].
The aim of the current study is to assess the validity of the
Japanese language version of the CSB (CSB-J) in Japanese patients
with schizophrenia by comparing performance on this battery to
that of the Japanese language version of the BACS (BACS-J)
already validated for use in Japan.
Methods
Subjects
Forty patients with schizophrenia were recruited at Chiba
University Hospital (Chiba, Japan), The University of Tokyo
Hospital (Tokyo, Japan), National Center Hospital, National
Center of Neurology and Psychiatry (Tokyo, Japan), Toyama
University Hospital (Toyama, Japan), and Tokushima University
Hospital (Tokushima, Japan). All patients met the DSM-IV
criteria for schizophrenia. No patient had received electroconvul-
sive therapy. There were no specific medication criteria for
inclusion in the patient group. Twenty-five of 40 patients were
treated with a single second-generation antipsychotic medication
(risperidone, n=8; aripiprazole, n=7; olanzapine, n=6; peros-
pirone, n=3; quetiapine, n=1), four patients were treated with a
single first-generation antipsychotic (haloperidol, n=1; fluphen-
azine, n=1; bromperidol, n=1; sulpiride, n=1), nine patients
were treated with a combination of antipsychotic drugs (aripipra-
zole and quetiapine, n=2; risperidone and quetiapine, n=1;
risperidone and haloperidol, n=1; risperidone and levomepro-
mazine, n=1; haloperidol and levomepromazine, n=1; haloper-
idol and zotepine, n=1; risperidone, haloperidol, and bromper-
idol, n=1; risperidone, haloperidol, and zotepine, n=1), and two
patients were medication free. Only two female patients were
inpatients.
Forty healthy controls were recruited at the same five sites.
They were screened with the Structured Clinical Interview for
DSM-IV Axis I Disorders, Non-Patient Edition and were required
not to have an Axis I disorder according to DSM-IV criteria. None
had a first-degree family history of schizophrenia or schizoaffective
disorder.
Inclusion criteria for all subjects in both groups included
proficiency in Japanese language, normal or corrected-to-normal
visual function, and at least a 9th-grade education. Exclusion
criteria for all subjects in both groups included any current or past
histories of neurological disorders (other than schizophrenia for the
patient group), including head injury, cerebral vascular disorders,
epilepsy, or alcohol or drug use disorders. No subject was treated
with donepezil. Participants who had severe symptoms of
depression (defined by the Japanese version of the Calgary
Depression Scale for Schizophrenia (JCDSS) [20,21] score of
more than 9) were excluded from the study. Smokers were
excluded because nicotine and nicotine withdrawal might have
effects on cognition.
Study investigators made a concerted effort to recruit healthy
controls who would match the patients on age, male/female ratio,
and premorbid intelligence quotient (IQ) as assessed by the
Japanese Adult Reading Scale-25 words version (JART-25) [22],
which is Japanese version of National Adult Reading Test. Age
was considered the primary demographic variable of interest since
it was likely to have the greatest impact on cognition. The 40
subjects of both groups were divided into 4 age groups (1, 20–29
years old; 2, 30–39 years old; 3, 40–49 years old; 4, 50–65 years
old). Prior to commencement of the study, all subjects provided
written informed consent after receiving a full explanation
regarding the nature of the study and potential risks and benefits
of study participation. The study was approved by the relevant
ethics committee of each institute and performed in accordance
with the Declaration of Helsinki II. The ethics committees of each
institute were: the Ethics Committee of Chiba University
Graduate School of Medicine (Chiba, Japan), the Ethical
Committee of the Faculty of Medicine, University of Tokyo
(Tokyo, Japan), the Ethics Committee of National Center of
Neurology and Psychiatry (Tokyo, Japan), the Committee on
Medical Ethics of Toyama Medical and Pharmaceutical Univer-
sity (Toyama, Japan), and the Ethics Committee of University of
Tokushima (Tokushima, Japan).
Assessment procedures
All subjects completed two batteries of cognitive tests admin-
istered by trained psychiatrists or psychologists. All subjects
received the CSB-J followed by the BACS-J version A. JART-25
was completed after the BACS-J. All subjects were tested in a
single day. In addition, the Positive and Negative Syndrome Scale
(PANSS) [23] was completed along with the BACS-J. Short breaks
of five minutes or less were provided as needed throughout testing.
Subjects were instructed to avoid caffeine in all forms from
20 minutes prior to assessments to the end of all tests.
The CSB-J consists of eight tasks that measure verbal learning
(International Shopping List Task; ISLT), speed of processing
(Detection Task; DET), attention/vigilance (Identification Task;
IDN), visual working memory (One Back Task; ONB), visual
memory (One Card Learning Task; OCL), spatial working
memory (Continuous Paired Association Learning Task; CPAL),
reasoning and problem solving (Groton Maze Learning Task;
GML), and social cognition (Social Emotional Cognition Task;
SECT). The primary measure from each task of the CSB-J was
standardized by creating Z-scores whereby healthy control mean
was set to zero and the standard deviation set to one, following the
methodological procedure used by Keefe et al. [14]. A composite
score was calculated by averaging all Z-scores of the eight primary
measures from the CSB-J. In this study, we used the original
version of the CSB with a slight modification. First, the Two Back
Task was omitted to reduce test duration because we considered
the ONB sufficient to assess working memory function [19].
Second, the CPAL can provide another non-verbal paired
associate learning [24]. Third, the list of words in the ISLT was
customized for the study as recommended by the authors to match
regional Japanese culture and minimize cross-cultural test bias
[25]. Fourth, stimuli in the SECT were also customized to only
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race effects that can occur on tasks that use representations of
human faces [26].
The CSB-J data were uploaded to a secure account on the
CogState server (http://www.cogstate.com). Uploaded outcome
parameters were calculated using custom software blind to
diagnosis. Logarithmic and arcsine transformations for speed
and accuracy measures respectively were performed in order to
avoid violation of necessary statistical preconditions. A description
of the battery’s administration and the eight cognitive tasks has
been reported previously for non-Japanese subjects [19,27].
Data analysis
Student’s t-test and Fisher’s exact test were used to examine
differences between groups. For the analysis of concurrent
validity, Pearson product-moment correlations were computed
between scores on subtests of the CSB-J and the BACS-J within
each cognitive domain. Stepwise General Linear Models (GLM)
with the CSB-J composite score or subscores as the dependent
variable were conducted. At first, with combined patients’ and
controls’ data, GLM were used to evaluate the effects of the
following independent variables on cognitive performance: age,
sex, premorbid IQ, education, JCDSS score. Second, with
patients’ data, GLM were used to evaluate the effects of the
following independent variables on cognitive performance: age,
gender, premorbid IQ, illness duration, duration of untreated
psychosis (DUP), the dosage of antipsychotic medication, the
dosage of anticholinergic medication, PANSS positive syndrome
scale score, PANSS negative syndrome scale score, PANSS
general psychopathology scale score. The structure of the CSB-J
was determined by performing the Maximum Likelihood
extraction methods with oblique rotation. The Kruskal-Wallis
test was used to compare cognitive impairment among different
subtypes of schizophrenia. Values of p,0.05 were considered to
indicate statistical significance.
Results
Demographic data and clinical variables
Demographic and clinical variables are presented in Table 1.
Age, gender, estimated premorbid IQ and education did not differ
for the two groups. The JCDSS score in patients was significantly
higher than that of healthy controls, indicating that the
schizophrenia patients group suffered more depressive symptoms.
Missing data across all sessions and administration time
The total amount of missing data across all tasks within the
CSB-J was 1.25%. The reason for missing data was the time
restriction of each subtest of the CSB-J. There was no missing data
for the BACS-J subtests. The total administration time of the CSB-
J (51.1612.2 min (mean 6 SD)) was significantly (t=10.719,
p,0.001) longer than that of the BACS-J (35.664.4 min (mean 6
SD)).
Validity and stepwise analysis
Figure 1 and 2 shows the performance of patients on each of the
primary measures and composite score of the CSB-J and the
BACS-J compared to the healthy control, respectively. Significant
differences in scores between the patients and the controls were
observed for all of the subtests of the CSB-J and the BACS-J.
The CSB-J composite score was significantly correlated with the
BACS-J composite score (r=0.709; p,0.001 for patients,
r=0.483; p,0.01 for controls; r=0.760; p,0.001 for total
subjects) as shown in Table 2 and Figure 3. Stepwise GLM
showed that age and premorbid IQ were independent predictors
of the CSB-J composite scores. Lower cognitive performance was
associated with increased age and lower premorbid IQ. After
accounting for age and premorbid IQ, the difference between both
composite scores remained. Other clinical variables were not
correlated with the CSB-J composite score.
Next, we examined correlations between corresponding subtests
from the CSB-J and the BACS-J. Because the BACS-J includes
only four of the seven cognitive domains selected by the
MATRICS initiative, we examined correlations of corresponding
subtests in only these four domains. ISLT score and DET score
were significantly correlated with the BACS-J verbal memory
score (r=0.725, p,0.001) and the BACS-J symbol coding score
(r=0.466, p,0.01) in patients, respectively. There were no
significant correlations between other corresponding subtests
(Table 2).
Furthermore, we examined the effect of five subtypes of
schizophrenia on the CSB-J scores in patients with schizophrenia
although the number of each subtype was small. The CSB-J score
in each subtype is shown in Table S1. The disorganized subtype
(n=3) demonstrated intact cognition. The paranoid subtype
(n=20) and the catatonic subtype (n=4) performed significantly
worse on ISLT and the CSB-J composite score than controls. The
undifferentiated subtype (n=4) performed significantly worse on
ISLT, IDN, and composite score than controls. The residual
subtype (n=9) performed significantly worse on broader domains
than controls, and had stronger impairment on the CSB-J
composite score (Figure 4 and Table S1).
Factor analysis of the CSB-J subtests
In a factor analysis of the CSB-J, the eigenvalue-greater-than-
one rule and scree plot converged on a three-factor solution that
accounted for 53.8% of the total variance. The Kaiser-Mayer-
Olkin measure was calculated at 0.587 and Bartlett’s test of
sphericity was significant at p,0.001. The factor loadings are
presented in Table 3. Subtests that needed memory loaded on
Factor 1, including CPAL, OCL, ISLT, and GML. Subtests that
needed speed loaded on Factor 2, including DET and IDN. The
SECT loaded on Factor 3. The ONB was not associated with this
three-factor solution.
Discussion
The present study is the first one to report the use of a complete
MCCB compatible battery in Japanese schizophrenia patients and
shows that the CSB-J is a useful neuropsychological battery for
assessing global cognitive impairment in Japanese patients with
schizophrenia. The CSB-J was easy to use and well tolerated by
patients with a 98.8% completion rate and acceptable adminis-
tration time with mean of 51.1 minutes. Although the adminis-
tration time of the CSB-J was about 15 minutes longer than that of
the partial MCCB BACS-J battery (with average of 35.6 minutes
administration duration), the difference was probably in part
because the CSB-J covered more cognitive domains than the
BACS-J. In addition, there was a significant correlation between
the CSB-J and the BACS-J composite scores in both the patients
with schizophrenia and healthy control subjects groups, consistent
with the previous results using the original English version of the
CSB and standardized tests and the MCCB [18,19].
The results of this study also provide evidence of good construct
validity for verbal memory and attentional domains between the
CSB-J and BACS-J tasks, which are considered to evaluate these
abilities. In particular, the ISLT and DET scores of the CSB-J
were significantly correlated with the verbal memory and the
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However, there were no significant correlations between the other
subscores of the CSB-J and the corresponding subscores of the
BACS-J that are considered to evaluate speed of processing,
working memory, and reasoning and problem solving. These
differences presumably relate to different task requirements. For
example, the BACS-J token motor test requires an ability to
coordinate both hands simultaneously, whilst the CSB-J IDN task
requires simpler motor abilities for pushing the response buttons.
Prior good correlations for the IDN task and information
processing speed measures have been reported in non-Japanese
schizophrenic patients [18], and a poor correlation between the
token motor test and a corresponding conventional test [14,28],
suggest that these tests measure differing abilities. Likewise, verbal
fluency is associated with multiple cognitive abilities, including
speed of processing, reasoning ability and other aspects of
executive function such as inhibition [29]. Similarly, the tasks
evaluating working memory from the different batteries had
significant differences. The ONB and CPAL tasks using the CSB-J
probably correlate with visual and spatial working memory, whilst
the digit sequencing of the BACS-J may correlate less with visual
and more with verbal working memory. With respect to reasoning
and problem solving, although both the GML task of the CSB-J
and the Tower of London from the BACS-J require planning,
inhibition, and working memory, the latter has been considered
more of a planning task [30], whereas the GML task appears to
highlight spatial working memory abilities [31]. Differences
between the constructs evaluated by these two batteries appear a
more salient explanation for the lack of correlations, since both the
CSB-J subtests and the BACS-J subtests have been reported to be
significantly correlated with the corresponding standard battery
subscores [15,19].
The factor analysis performed on the CSB-J suggests that three
factors of cognitive performance can be derived from the CSB-J
scores. The first factor had memory as a common ability and
included the CPAL, OCL, ISLT, and GML tasks. A second speed
Table 1. Demographic and symptom information.
Controls (n=40) Patients (n=40) p-value
Age (years) 39.6611.9 (22–59) 39.6612.3 (22–65) 1.000
Male/Female 20/20 20/20 1.000
Premorbid IQ 107.168.5 (89–120) 103.7610.1 (79–120) 0.114
Education (years) 15.061.8 (12–20) 14.362.0 (10–20) 0.139
JCDSS 0.661.4 (0–6) 2.262.4 (0–9) 0.001
Illness duration (years) 15.6611.6 (2–38)
Duration of untreated psychosis (years) 2.566.0 (0–37)
Chlorpromazine equivalents (mg) 410.86305.6 (0–1250)
Biperiden equivalents (mg) 1.061.9 (0–6)
PANSS positive 14.165.2 (6–24)
PANSS negative 17.966.1 (9–36)
PANSS general 33.1610.9 (18–47)
Data are the mean 6 S.D. Parenthesis is the range.
JCDSS: the Japanese version of Calgary Depression Scale for Schizophrenia.
PANSS: Positive and Negative Syndrome Scale.
doi:10.1371/journal.pone.0020469.t001
Figure 1. Magnitude of impairment relative to matched
healthy controls on each cognitive measure from the CSB-J.
Abbreviation: ISLT International Shopping List Task, DET Detection Task,
IDN Identification Task, OCL One Card Learning Task, ONB One Back
Task, CPAL Continuous Paired Association Task, GML Groton Maze
Learning Task. Numbers of the figure are Z-score. *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0020469.g001
Figure 2. Magnitude of impairment relative to matched
healthy controls on each cognitive measure from the BACS-J.
Numbers of the figure are Z-score. All subtests and composite score
were p,0.001.
doi:10.1371/journal.pone.0020469.g002
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third factor separated out the SECT task, which includes abilities
collectively considered important in social cognition. It has been
suggested that social cognition represents a separate cognitive
domain in schizophrenia [32]. Social cognitive ability is considered
to be an important predictor of effective social [33] and
community function (including interpersonal relationships and
work functioning) independent of abilities in other cognitive
domains [34,35]; however we did not perform additional social
and community functional assessments in this study. Taken
together, the CSB-J may have an advantage over the BACS-J
because the BACS-J lacks a social cognition subtest.
Although the numbers of each diagnostic subtype of schizo-
phrenia were small in this study, we did find that each subtype had
a quite different profile of CSB-J score. Both the undifferentiated
subtype and the residual subtype had major cognitive impairment
on the CSB-J composite score, consistent with previous reports
[36,37]. In contrast, Brazo et al. [38] reported that the
disorganized subtype had major cognitive impairments, whereas
in our study the disorganized subtype had intact cognitive
function. The reasons underlying this discrepancy are currently
unknown. Clearly a larger sample will be required to further
investigate this issue.
There are some limitations of this study. First, some subtests of
the CSB-J were not assessed in the criterion-related validity
analysis. This is because of the absence of equivalent MCCB
domain specific tests for Japanese. Second, the assessment of social
cognition by emotional perception alone does not cover many of
the putative abilities thought to underlie this complex behavior.
Further studies will be required if other social and emotional
cognitive tasks are adapted for Japanese patients. Third, the
sample size of this study was small (n=40 for each group), and
larger studies would aid in confirming and extending the findings
of the current study. Further detailed studies of the CSB-J in
comparison to a complete Japanese language version of the
MCCB and other social cognitive abilities such as theory of mind
and attributional style would help determine the applicability of
this promising battery. Furthermore, the current study did not
repeat the batteries precluding assessment of test-retest validity,
which is considered by the MATRICS initiative investigators a
vital feature of a test battery to be used in clinical trials of
schizophrenia [11]. Since test-retest results have been reported for
both the CSB and the MCCB in non-Japanese control subjects
and schizophrenic patients [39–41], such studies using Japanese
samples are recommended.
Figure 3. Inter-correlations between the CSB-J composite score
and the BACS-J composite score. Controls: r=0.483; p,0.01,
Patients: r=0.709; p,0.001, Total subjects: r=0.760; p,0.001.
doi:10.1371/journal.pone.0020469.g003
Table 2. Correlation efficiencies between the CSB-J and the BACS-J for the same cognitive domains.
Cognitive domain Patients Controls Totals
Verbal learning International Shopping List Task vs. BACS-J Verbal memory .725*** .424** .714***
Speed of processing Detection Task vs. BACS-J Token motor .105 .025 .207
Detection Task vs. BACS-J Verbal fluency 2.184 2.031 2.003
Detection Task vs. BACS-J Symbol coding .466** 2.167 .341**
Working memory One back Task vs. BACS-J Digit sequencing .169 2.041 .181
Continuous Paired Association Task vs. BACS-J Digit sequencing .192 .284 .342**
Reasoning and problem solving Groton Maze Learning Task vs. BACS-J Tower of London .135 .276 .250*
Composite Score The CSB-J Composite Score vs. The BACS-J Composite Score .709*** .483** .760***
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0020469.t002
Figure 4. Effects of subtype on CSB-J composite score in
patients with schizophrenia. Number of the figure is Z-score.
*P,0.05, **P,0.01 as compared with control.
doi:10.1371/journal.pone.0020469.g004
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sensitive to cognitive impairment in Japanese patients with
schizophrenia, and that the CSB-J composite score was signifi-
cantly correlated with the BACS-J composite score providing
initial criterion and construct validation. Although further studies
are required to address test-retest validity, the CSB-J appears to be
a promising cognitive battery to assess the therapeutic effects on
potential cognitive-enhancing agents in Japanese patients with
schizophrenia.
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Table S1 The CSB-J subscores of each subtype of
schizophrenia. *p,0.05, **p,0.01 (for post-hoc analysis).
Kruskal-Wallis tests; post-hoc tests; comparison between each
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